

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants : Ann Marie Schmidt and David Stern

Serial No. : 09/167,705 Examiner: F. Hamud

Filing Date : October 6, 1998 Art Unit: 1646

For



EXTRACELLULAR NOVEL RAGE BINDING PROTEIN  
(EN-RAGE) AND USES THEREOF

1185 Avenue of the Americas  
New York, New York 10036  
January 7, 2000

Assistant Commissioner for Patents  
Washington, D.C. 20231

Sir:

STATEMENT IN ACCORDANCE WITH 37 C.F.R. §1.821(f)

In accordance with 37 C.F.R. §1.821(f), I hereby certify that the computer readable form containing the nucleic acid and/or amino acid sequences required by 37 C.F.R. §1.821(f) and submitted in connection with the above-identified application, has the same content as that submitted herewith as **Exhibit B** entitled "Sequence Listing."

Respectfully submitted,

A handwritten signature in cursive script, appearing to read "Jane M. Love".

Jane M. Love, Ph.D.  
Registration No. 42,812  
c/o Cooper & Dunham LLP  
1185 Avenue of the Americas  
New York, New York 10036  
(212) 278-0400

C

# SEQUENCE LISTING

T0480' <110> Schmidt, Ann Marie  
Stern, David

<120> Extracellular Novel RAGE Binding Protein (EN-RAGE) and  
Uses Thereof

<130> 0575/55873

<140> 09/167,705

<141> 1998-10-06

<160> 5

<170> PatentIn Ver. 2.1

<210> 1

<211> 395

<212> DNA

<213> Bovine

<400> 1

atgactaagc tggaggacca cctggaggga atcatcaaca tcttccacca gtactccgtt 60  
cggtgtgggc atttcgacac cctcaacaag cgtgagctga agcagctgat cacaaaggga 120  
acttcccaaaa accctccaga acaccaaaga ccaacctacc attgacaaaa tattccaaga 180  
cctggatgcc gataaagacg gagccgtcag ctttgaggaa ttcgtagtcc tgggtgtccag 240  
ggtgctgaaa acagcccaca tagatatcca caaagagtag gtttccagca atgttcccaa 300  
gaagacttac ctttctctc cctgaggctg ctccccgagg gagagagaat tataaacgta 360  
ctttggcaaaa ttcttagcaa aaaaaaaaaa aaaaaa 395

<210> 2

<211> 50

<212> PRT

<213> Human

<220>

<221> UNSURE

<222> (47)

<223> Xaa at this position is unknown

<400> 2

Thr Lys Leu Glu Asp His Leu Glu Gly Ile Ile Asn Ile Gly His Gln  
1 5 10 15  
Tyr Ser Val Arg Val Gly His Phe Asp Thr Leu Asn Lys Tyr Glu Leu  
20 25 30

Lys Gln Leu Gly Thr Lys Glu Leu Pro Lys Thr Leu Gln Asn Xaa Lys  
35 40 45

Asp Gln  
50

<210> 3  
<211> 90  
<212> PRT  
<213> Human

<400> 3  
Thr Lys Leu Glu Asp His Leu Glu Gly Ile Ile Asn Ile Phe His Gln  
1 5 10 15

Tyr Ser Val Arg Val Gly His Phe Asp Thr Leu Asn Lys Arg Glu Leu  
20 25 30

Lys Gln Leu Ile Thr Lys Glu Leu Pro Lys Thr Leu Gln Asn Thr Lys  
35 40 45

Asp Gln Pro Thr Ile Asp Lys Ile Phe Gln Asp Leu Asp Ala Asp Lys  
50 55 60

Asp Gly Ala Val Ser Phe Glu Glu Phe Val Val Leu Val Ser Arg Val  
65 70 75 80

Leu Lys Thr Ala His Ile Asp Ile His Lys  
85 90

<210> 4  
<211> 18  
<212> PRT  
<213> Human

<400> 4  
Asp Gly Ala Val Ser Phe Glu Glu Phe Val Val Leu Val Ser Arg Val  
1 5 10 15

Leu Lys

<210> 5  
<211> 5

<212> PRT  
<213> Human

<400> 5

Ala Gln Asn Ile Thr  
1 5